NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech Inc. (Nasdaq: NKGN) announced upcoming poster presentations at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain from October 29 – November 1, 2024. The presentations will cover:
1. A final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in Alzheimer's disease subjects.
2. Further biomarker analysis and implications for use in prevention of Alzheimer's disease using non-genetically modified natural killer cells (SNK01) with enhanced activity.
The posters will be presented during Poster Session 1 on October 29-30, 2024. Full abstracts will be included in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD).
NKGen Biotech Inc. (Nasdaq: NKGN) ha annunciato presentazioni di poster in occasione della 17ª Conferenza Annuale sui Trial Clinici sulla Malattia di Alzheimer (CTAD) che si terrà a Madrid, Spagna, dal 29 ottobre al 1 novembre 2024. Le presentazioni tratteranno:
1. Un rapporto finale di uno studio di escalation della dose di Fase 1 e un rapporto preliminare del coorte di Fase 1 nello studio di follow-up di Fase 1/2a di troculeucel in soggetti affetti da malattia di Alzheimer.
2. Ulteriori analisi dei biomarcatori e implicazioni per l'uso nella prevenzione della malattia di Alzheimer utilizzando cellule natural killer non geneticamente modificate (SNK01) con attività potenziata.
I poster saranno presentati durante la Sessione di Poster 1 il 29 e 30 ottobre 2024. Gli abstract completi saranno inclusi nell'edizione speciale CTAD del Journal of Prevention of Alzheimer's Disease (JPAD).
NKGen Biotech Inc. (Nasdaq: NKGN) anunció presentaciones de carteles en la 17ª Conferencia Anual de Ensayos Clínicos sobre la Enfermedad de Alzheimer (CTAD) que se celebrará en Madrid, España, del 29 de octubre al 1 de noviembre de 2024. Las presentaciones abordarán:
1. Un informe final de un estudio de escalada de dosis de Fase 1 y un informe preliminar de la cohorte de Fase 1 en el estudio de seguimiento de Fase 1/2a de troculeucel en sujetos con enfermedad de Alzheimer.
2. Un análisis adicional de biomarcadores e implicaciones para su uso en la prevención de la enfermedad de Alzheimer utilizando células asesinas naturales no modificadas genéticamente (SNK01) con actividad mejorada.
Los carteles se presentarán durante la Sesión de Carteles 1 el 29 y 30 de octubre de 2024. Los resúmenes completos se incluirán en la edición especial CTAD del Journal of Prevention of Alzheimer's Disease (JPAD).
NKGen Biotech Inc. (Nasdaq: NKGN)는 2024년 10월 29일부터 11월 1일까지 스페인 마드리드에서 열리는 제17회 알츠하이머병 임상 시험 연례 회의(CTAD)에서 포스터 발표를 예정하고 있다고 발표했습니다. 발표 내용은 다음과 같습니다:
1. 알츠하이머병 환자에서 troculeucel의 1상 용량 증량 연구의 최종 보고서와 후속 1/2a 단계 연구의 1상 코호트에 대한 초안 보고서.
2. 비유전자 변형 자연 킬러 세포(SNK01)를 이용한 알츠하이머병 예방을 위한 바이오마커 추가 분석 및 활용에 대한 함의.
포스터는 2024년 10월 29일부터 30일까지 포스터 세션 1에서 발표될 예정입니다. 전체 초록은 알츠하이머병 예방 저널(JPAD)의 CTAD 특별판에 포함될 것입니다.
NKGen Biotech Inc. (Nasdaq: NKGN) a annoncé des présentations de posters à venir lors de la 17e Conférence Annuelle sur les Essais Cliniques dans la Maladie d'Alzheimer (CTAD) qui se tiendra à Madrid, en Espagne, du 29 octobre au 1 novembre 2024. Les présentations couvriront :
1. Un rapport final d'une étude d'escalade de dose de Phase 1 et un rapport préliminaire du groupe de Phase 1 dans l'étude de suivi de Phase 1/2a sur le troculeucel chez des sujets atteints de la maladie d'Alzheimer.
2. Une analyse supplémentaire des biomarqueurs et les implications pour l'utilisation dans la prévention de la maladie d'Alzheimer en utilisant des cellules tueuses naturelles non modifiées génétiquement (SNK01) avec une activité améliorée.
Les posters seront présentés lors de la Session de Posters 1 les 29 et 30 octobre 2024. Des résumés complets seront inclus dans l'édition spéciale CTAD du Journal of Prevention of Alzheimer's Disease (JPAD).
NKGen Biotech Inc. (Nasdaq: NKGN) kündigte bevorstehende Poster-Präsentationen auf der 17. Jahrestagung zur klinischen Forschung an der Alzheimer-Krankheit (CTAD) in Madrid, Spanien, vom 29. Oktober bis 1. November 2024 an. Die Präsentationen werden Folgendes behandeln:
1. Einen Abschlussbericht einer Phase-1-Dosiserhöhungsstudie und einen vorläufigen Bericht der Phase-1-Kohorte in der Folge-Phase-1/2a-Studie von troculeucel bei Alzheimer-Patienten.
2. Weitere Biomarkeranalysen sowie deren Implikationen für die Verwendung zur Prävention der Alzheimer-Krankheit unter Einsatz von nicht genmanipulierten natürlichen Killerzellen (SNK01) mit verbesserter Aktivität.
Die Poster werden während der Poster-Session 1 am 29. und 30. Oktober 2024 präsentiert. Vollständige Abstracts werden in der speziellen CTAD-Ausgabe des Journal of Prevention of Alzheimer's Disease (JPAD) veröffentlicht.
- Presentation of Phase 1 results for troculeucel in Alzheimer's disease at a major conference
- Ongoing Phase 1/2a study of troculeucel in Alzheimer's disease
- Further biomarker analysis of SNK01 in Alzheimer's disease prevention
- None.
SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in subjects with Alzheimer’s disease, at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference (“CTAD”) to be held in Madrid, Spain from October 29 – November 1, 2024.
Presentation Details:
| Title: | Treatment of Moderate Alzheimer’s Disease Subjects with Expanded Non-genetically Modified Natural Killer Cells (troculeucel; SNK01) with Enhanced Activity – Report of the Phase I results of the Phase I/IIa Study |
| Authors: | Paul Y. Song, Lucia Hui, Hank Lee, Juan Mata, Katia Betito, Harry Chung, Jesse Carr |
| Session Title: | Poster Session 1 - Theme 02: Clinical Trials: Results |
| Poster Number: | LP020 |
| General Session Time: | Tuesday, October 29, 2024, 3:00 pm to Wednesday, October 30, 2024 – 5:00 pm CET |
Presentation Details:
| Title: | Use of Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer’s Disease. Further Biomarker Analysis and Implications for Use in Prevention |
| Authors: | Paul Song, Clemente Humberto Zúñiga Gil, Blanca Isaura Acosta Gallo, Cesar Alejandro Amescua, Rufino Menchaca Díaz, Sean Hong, Juan Mata, Katia Betito, Hank Lee, Yoonmi Kang, Lucia Hui |
| Session Title: | Poster Session 1 – Theme 04: Clinical Trials: Biomarkers Including Plasma |
| Poster Number: | P105 |
| General Session Time: | Tuesday, October 29, 2024, 3:00 pm to Wednesday, October 30, 2024 – 5:00 pm CET |
A copy of the posters will be added to the Scientific Publications page of the Company’s website at https://nkgenbiotech.com/ once presentations have concluded.
Full abstracts accepted as poster presentations will also be included in the special CTAD edition of the Journal of Prevention of Alzheimer’s Disease (JPAD), the official journal of the CTAD conference.
About Troculeucel
Troculeucel is a novel cell-based, patient specific ex vivo expanded autologous natural killer (“NK”) cell, immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on our journey toward bringing this therapy to market.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
External Contacts:
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
What is NKGen Biotech presenting at the CTAD Conference 2024?
When and where is the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) taking place?
What is troculeucel and how is it being studied by NKGen Biotech (NKGN)?
Where can investors find NKGen Biotech's (NKGN) CTAD 2024 poster presentations after the conference?
